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GABAA receptors are pentameric ligand-gated ion channels in-
volved in fast inhibitory neurotransmission and are allosterically
modulated by the anxiolytic, anticonvulsant, and sedative-hypnotic
benzodiazepines. Here we show that the prokaryotic homolog ELIC
also is activated by GABA and is modulated by benzodiazepines
with effects comparable to those at GABAA receptors. Crystal struc-
tures reveal important features of GABA recognition and indicate
that benzodiazepines, depending on their concentration, occupy
two possible sites in ELIC. An intrasubunit site is adjacent to the
GABA-recognition site but faces the channel vestibule. A second
intersubunit site partially overlaps with the GABA site and likely
corresponds to a low-afﬁnity benzodiazepine-binding site in GABAA
receptors that mediates inhibitory effects of the benzodiazepine
ﬂurazepam. Our study offers a structural view how GABA and ben-
zodiazepines are recognized at a GABA-activated ion channel.
GABA (γ-aminobutyric acid) is one of the most importantinhibitory neurotransmitters in the central nervous system,
and its effects are mediated mostly through ionotropic GABAA
receptors. These proteins belong to the family of pentameric
ligand-gated ion channels (pLGICs), which includes glycine,
nicotinic acetylcholine, and 5-HT3 receptors. GABAA receptors
are heteropentamers, with a majority of receptors composed of
two α, two β, and one γ2 subunit. They contain two binding sites
for GABA, which have been localized to two β/α interfaces
formed by the principal (+) face of the β-subunit and the com-
plementary (−) face of the α-subunit. GABAA receptors are
modulated by a variety of clinically used drugs, including ben-
zodiazepines, barbiturates, neuroactive steroids, and anesthetics
(1). Benzodiazepines, such as diazepam and ﬂurazepam, modu-
late GABAA receptors through binding at an extracellular
intersubunit site formed between the principal (+) face of the
α-subunit and the complementary (−) face of the γ2-subunit (2).
Benzodiazepines are among the most widely prescribed psy-
choactive drugs worldwide because of their anxiolytic, anticon-
vulsant, muscle relaxant, and sedative-hypnotic effects. More
recently developed nonbenzodiazepine hypnotics, such as zopi-
clone and zolpidem, differ in chemical structure from the classical
benzodiazepines but also act as positive allosteric modulators at
GABAA receptors through the benzodiazepine-binding site.
Amino acids that form the recognition sites for both GABA and
benzodiazepines are located on six noncontiguous regions his-
torically designated as loops A, B, and C on the principal (+) face
of the binding site and D, E, and F on the complementary (−) face
of the binding site (Fig. 1A and SI Appendix, Fig. S1).
Binding-site residues contributing to recognition of both
GABA and benzodiazepines previously have been studied ex-
tensively by mutagenesis. Both natural (3, 4) and unnatural
amino acid mutagenesis (5, 6) have demonstrated that inter-
actions between the γ-amino nitrogen of GABA and aromatic
side chains of loop A in the GABAA receptor and loop B in the
GABAC receptor are crucial for recognition of GABA (sum-
marized in SI Appendix, Table S1). In addition, it has been
suggested that the GABA carboxylate group is stabilized through
electrostatic interactions with Arg residues on the principal and
complementary faces of the binding site (4, 7–9). For benzo-
diazepines, the individual contributions of residues in loops A–F
of the high-afﬁnity binding site have been investigated exten-
sively (for a recent review, see ref. 10. or references given in SI
Appendix, Table S2). In brief, several studies have revealed the
importance of a histidine residue in loop A (11, 12) and of
several aromatic residues on the principal and complementary
faces of the benzodiazepine-binding site (13–18).
Despite these insights, detailed understanding of the nature of
these interactions is currently lacking because of the absence
of X-ray crystal structures for eukaryote GABAA receptors. Re-
cently, however, the crystal structures of two prokaryotic pLGICs,
namely ELIC (19) and GLIC (20, 21), and the glutamate-gated
chloride channel from Caenorhabditis elegans, GluCl (22), have
revealed the molecular architecture of closed and open pLGICs.
In this study, we show that ELIC is activated by GABA and
modulated by benzodiazepines. Crystal structures of ELIC in
complex with GABA and different benzodiazepines reveal the
structural architecture of ligand recognition and provide a struc-
tural framework to understand both the enhancement and the
inhibition of GABA-elicited responses by benzodiazepines.
Results and Discussion
ELIC Is Activated by GABA and Modulated by Benzodiazepines. Using
high-throughput electrophysiological techniques, we screened a li-
brary of compounds composed of natural amino acids, photosyn-
thesis intermediates, neurotransmitters, agonists, and known
modulators of ligand-gated ion channels. We discovered that ap-
plication of GABA to Xenopus oocytes expressing ELIC produced
concentration-dependent, rapidly activating inward currents, which
desensitized slowly (Fig. 1B). From plotting current amplitude
against a series of GABA concentrations, we calculated an EC50 of
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21 mM [pEC50 (−log value of EC50): 1.69 ± 0.03, n= 4] on ELIC,
a value that is ∼400-fold greater than at α1β3γ2 GABAA receptors
(EC50 = 50 μM). When calcium was omitted from the extracellular
recording solution (SI Appendix, Fig. S2), we observed a decrease
in the rate of activation and desensitization and an increase in
sensitivity to GABA (EC50 = 7.3 mM; pEC50: 2.14 ± 0.02, n = 5).
This effect was not ablated by 1,2-bis(o-aminophenoxy)ethane- N,
N,N’,N’-tetraacetic acid (BAPTA) or compounds that block en-
dogenous Ca2+-activated Cl− channels in oocytes (SI Appendix,
Fig. S2), suggesting that calcium modulates GABA sensitivity and
channel function in ELIC directly. Other known agonists for
GABAA receptors, including muscimol and THIP (4,5,6,7-Tetra-
hydroisoxazolo[5,4-c]pyridin-3-ol hydrochloride), had no effect on
ELIC (1–10 mM, n = 4). Zimmermann and Dutzler (23) reported
that ELIC could be activated by a series of primary amines, in-
cluding GABA. These authors also demonstrated that ELIC forms
cation-selective channels with a large single-channel conductance,
making it a suitable model channel to study the molecular mech-
anisms underlying ligand recognition and coupling of ligand
binding to channel opening in the family of pLGICs. Very recently,
Pan et al. (24) reported a crystal structure of ELIC in complex with
acetylcholine, which acts as an antagonist at this channel. However,
high-resolution acetylcholine-bound structures already have been
determined in complex with acetylcholine-binding proteins from
eukaryotes (25, 26), which are better homologs of the nicotinic
acetylcholine receptor than the distant, prokaryotic ELIC struc-
ture. In contrast, no structural data are currently available that
provide detailed insight into the recognition of GABA and allo-
steric modulators such as benzodiazepines.
Next, we investigated the effect on ELIC of a series of GABAA-
receptor modulators, including benzodiazepines, barbiturates,
neuroactive steroids, and nonbenzodiazepine hypnotics. The ef-
fect of these compounds was characterized by coapplication with
an EC3 or EC10 concentration of GABA. Some compounds, such
as alphaxalone and pentobarbital, had no signiﬁcant effect on
ELIC (white bars in Fig. 1D), suggesting that the binding sites
for these modulators have not yet been formed at this stage of
evolution or that these compounds bind to ELIC but have no
effect on channel function. Others had an effect opposite that at
GABAA receptors (gray bars in Fig. 1D): Propofol and zopiclone
have inhibitory effects on ELIC, although both compounds po-
tentiate GABA responses in human GABAA receptors. Bicu-
culline, which acts as an antagonist at most GABAA receptors,
potentiates ELIC responses, an effect also seen at homomeric
β3 GABAA receptors (27). Some compounds, however, affect
ELIC similarly to GABAA receptors (black bars in Fig. 1D). For
example, ﬂurazepam potentiates ELIC responses up to 180 ±
27% (n = 6, P < 0.05) at 50 μM, but at higher concentrations
it inhibits GABA-induced currents (Fig. 1C). These effects are
similar to the biphasic effect of ﬂurazepam on GABAA recep-
tors, which has been attributed to an interaction of ﬂurazepam
with a high- and a low-afﬁnity binding site at these receptors (28,
29). Bromo-analogs of ﬂurazepam and ﬂunitrazepam (here termed
“Br-ﬂurazepam” and “Br-ﬂunitrazepam,” respectively) (SIAppendix,
Fig. S3), which facilitate structural studies, also potentiated the
GABA response to 150 ± 9% (n = 4, P < 0.05) and 175 ± 17%
(n = 4, P < 0.05), respectively (black bars in Fig. 1D).
Flurazepam potentiates the GABA response with an EC50 of
12.5 μM (pEC50: 4.90 ± 0.26, n = 4), which is ∼30-fold higher
than that at GABAA receptors (EC50 of 0.39 μM; pEC50: 6.41 ±
0.14, n = 6). Potencies of drugs usually are lower in bacterial
proteins than in mammalian proteins. For example, the bacterial
neurotransmitter sodium symporter LeuT displays afﬁnities for
tricyclic antidepressants, such as clomipramine and imipramine,
that are more than 200-fold lower than for their binding sites in
human symporters (30, 31). Nevertheless, binding mechanisms
and molecular determinants for drug actions often are conserved
throughout evolution.
Together, these results demonstrate that ELIC is a potentially
useful model to study GABA recognition and channel modulation
by known allosteric modulators of the GABAA receptor, including
the benzodiazepine ﬂurazepam and the nonbenzodiazepine hyp-
notic zopiclone. In addition, combined with previous data showing
Fig. 1. ELIC is a bacterial GABA-gated channel, which is modulated by
benzodiazepines. (A) (Left) X-ray crystal structure of ELIC in complex with
GABA showing the location of the GABA-binding site between the principal
(yellow) and complementary (blue) subunits. GABA is shown in spherical
representation. (Right) Close-up view showing the different loops (A–G) that
contribute to the ligand-binding site. (B) Typical traces of concentration-
dependent GABA-induced current recorded from oocytes injected with ELIC.
Horizontal bars indicate duration of agonist application. (C) Flurazepam
(black bars) biphasically modulates the GABA-induced current. (D) Applica-
tion of a range of GABAA-receptor modulators [10 μM each, except propofol
(100 μM), etazolate (30 μM), alphaxalone (100 μM), pentobarbital (1 mM),
ﬂurazepam (50 μM), and PK11195 (100 μM)] to 3–5 mM GABA-induced ELIC
currents shows that the effects of some GABAA-receptor modulators are
conserved in ELIC. No modulators had effects when applied alone. Data are
mean ± SEM, n = 3–5. *P < 0.05.
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GABA modulation of benzodiazepine-binding sites in insects (32,
33), these results establish a clear evolutionary link between bac-
terial and eukaryote pLGICs. Previous studies have shown that
GABA plays a role in quorum sensing (34) in certain bacteria,
including Erwinia species (35), indicating that specialized recep-
tors involved in GABA signaling possibly arose during the early
evolution of proteobacteria.
Molecular Recognition of GABA. To understand the structural basis
for molecular recognition of GABA and benzodiazepines, we de-
termined three separate cocrystal structures of ELIC with GABA
and ﬂurazepam, Br-ﬂurazepam, and the nonbenzodiazepine mod-
ulator zopiclone. Depending on the relative amounts of compounds
used during cocrystallization conditions, we found that benzo-
diazepines can localize to two different binding sites in ELIC
(see below).
First, we obtained 3.8-Å diffraction data from ELIC crystals
grown in the presence of excess GABA versus ﬂurazepam (SI
Appendix, Table S3). Although the resolution of these data is
relatively low, we observe clear peaks at 3σ in unaveraged Fo-Fc
omit electron density maps in two extracellular ligand-binding
sites at the subunit interface (SI Appendix, Fig. S4). This sausage-
shaped density, which we do not observe in crystals grown in the
absence of GABA (SI Appendix, Fig. S4), is sufﬁciently clear to
assign a likely binding pose for a GABA molecule. In agreement
with previous mutagenesis experiments of GABAA receptor
residues involved in ligand contacts with GABA (3, 6), we ﬁnd
that the γ-amino nitrogen of GABA interacts with the carbonyl
oxygen of F133 in loop B (Fig. 2A), which mimics the interaction
of the pyrrolidine N+-H of nicotine with the carbonyl oxygen of
W143 in loop B of acetylcholine-binding protein (AChBP) from
Lymnaea stagnalis (Fig. 2D) (25, 36). Also similar to nicotine in
AChBP, we ﬁnd that the amino-moiety of GABA is caged by
aromatic side chains of F133 (loop B), Y175 and F188 (loop C),
and Y38 (loop D) and forms a cation-π interaction with F133 and
F188 (Fig. 2A). In Lymnaea AChBP (Fig. 2D) (37), these resi-
dues correspond to W143 (loop B), Y192 (loop C), and W53
(loop D). Residue Y89, which forms loop A in AChBP, also
contributes an aromatic side chain to the binding pocket, but this
residue is not conserved in ELIC (I79). We observe that R190 in
loop C of ELIC is involved in a hydrogen bond with the hydroxyl
group of Y175 (loop C), consistent with mutagenesis and mod-
eling data showing that the homologous residue in GABAC
receptors (R249 in ρ1) contributes to the structure of the binding
pocket through a salt bridge and/or hydrogen bond (9), although
the equivalent residue in GABAA receptors (R207 in β1) was
proposed to contact GABA directly (38). The observed GABA-
binding pose also is consistent with a low-resolution structure of
ELIC in complex with bromopropylamine (23) and the recently
determined crystal structure of GluCl in complex with glutamate
(22) (Fig. 2C). We ﬁnd that the α-amino nitrogen of glutamate
occupies a position that is almost identical (<1.0 Å) to the
γ-amino nitrogen of GABA and is involved in similar inter-
actions, including cation-π interactions with Y151 and Y200
(homologous to F133 and F188 in ELIC). Arginine residues of
loop D, which may stabilize the carboxyl tail of GABA in ver-
tebrate receptors (9, 39), are not conserved in ELIC (R67 in α1,
R104 in ρ1, R56 in GluCl, and V40 in ELIC). This difference
likely explains the different binding pose of the γ-carboxylate
group of glutamate and carboxyl tail of GABA (Fig. 2 A and C).
Because the resolution of the ELIC structure in complex with
GABA is relatively low, and GABA is a reasonably small and
symmetric molecule, we further investigated possible cation-π
interactions between the amino-moiety of GABA and the aro-
matic side chains of the intersubunit binding site by unnatural
amino acid mutagenesis. To facilitate this study, we took ad-
vantage of L240S-containing ELIC receptors, which have im-
proved GABA potency. Consistent with the described effects of
similar mutations at the 9′ position of the pore-lining M2 helix in
the nicotinic acetylcholine receptor (nAChR) (36, 40), we ﬁnd
that the L240S mutation in ELIC decreases the EC50 for GABA
to 4.2 mM (pEC50: 2.37 ± 0.03, n = 5). In the background of
L240S ELIC, we probed residues Y38 (loop D), F133 (loop B),
Y175 (loop C), and F188 (loop C) by incorporating a series of
ﬂuorinated phenylalanine derivatives. The data reveal a serial
decrease in agonist potency with increasing ﬂuorination, in-
dicative of a cation-π interaction, at positions 133 and 188 (Fig.
2B) but not at positions 38 and 175 (SI Appendix, Fig. S5). These
data make a strong argument for a cation-π interaction between
the γ-amino group of GABA and both the loop B and C aro-
matics, similar to our recent observation in an insect GABA
receptor (41). These data also are consistent with the assigned
binding pose for GABA in the crystal structure, which places
the amino moiety almost equidistant between the loop B and C
aromatic residues in the binding pocket.
Intrasubunit Benzodiazepine Site Facing the Channel Vestibule in
ELIC. The unaveraged Fo-Fc omit density map for the GABA-
bound ELIC structure shows strong density at 3.5σ (Fig. 3B and
SI Appendix, Fig. S6), which we interpreted as ﬂurazepam bound
in one subunit because it was present at relatively low amounts in
the crystallization solution. The difference density shows a pro-
trusion for the chlorine atom and the curvature for the benza-
zepine moiety, which allowed us to assign a likely binding pose
for ﬂurazepam. Unexpectedly, this density is localized at an
intrasubunit cavity facing the vestibule of the extracellular do-
main (Fig. 3A). This intrasubunit benzodiazepine-binding site is
Fig. 2. Locating GABA in the ELIC-binding pocket. (A) GABA is encompassed
by four aromatic residues (Y38, F133, Y175, and F188) in the binding pocket
and is in close proximity to N103 and V40. The amino-moiety of GABA forms
a hydrogen bond with the carbonyl oxygen of F133 in loop B, which mimics
the interaction of the pyrrolidine N+-H of nicotine with the carbonyl oxygen
of W143 in loop B of AChBP from L. stagnalis (25, 36) shown in D. Similar
interactions also are observed in the glutamate-bound structure of GluCl
(22) as shown in C. The γ-amino nitrogen of GABA also forms cation-π
interactions with F133 and F188, as corroborated by the plots shown in B.
Here the aromatic residues surrounding GABA were replaced with a range
of ﬂuorinated Phe or cyano-Phe, and relative EC50s were determined; a
linear relationship between the log ratio of EC50-values for wild type and
mutant and the cation-π binding energy, as seen for F133 and F188, is in-
dicative of a cation-π interaction.
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localized at the same height as the GABA intersubunit-binding
site but lies opposite the inner walls formed by loop B (+ face)
and loop D (− face) of the neighboring GABA-recognition site
(Fig. 3A). This benzodiazepine site is, in consequence, ideally
positioned to modulate GABA function allosterically in ELIC.
Interestingly, this density could be observed in only one subunit.
The slightly lower cavity volume of the other four subunits, which
might have resulted from a local asymmetry imposed by the
crystal lattice or the binding of one ﬂurazepam to ELIC, might
have prevented more ﬂurazepam molecules from binding.
To probe the contribution of the intrasubunit benzodiazepine-
binding site, we performed cysteine-scanning mutagenesis on
a selection of residues lining the intrasubunit benzodiazepine site
in ELIC. We found that potentiation of GABA responses by 50
μM ﬂurazepam was abolished in N60C (100 ± 5%, n = 4) and
I63C (100 ± 7%, n = 4) mutants (SI Appendix, Fig. S7 A and B).
These data indicate that the potentiating effects of ﬂurazepam
on ELIC arise from an interaction with the intrasubunit benzo-
diazepine site. An intrasubunit pocket exactly matching the
intrasubunit benzodiazepine site in ELIC has been identiﬁed in
the crystal structure of the muscle α1 nAChR subunit (42) and
was used in a structure-based drug-design approach for nAChR
modulators (43), indicating that the intrasubunit site in ELIC
also is conserved in eukaryote pLGICs. The possible existence of
a similar intrasubunit site in eukaryote GABAA receptors is sup-
ported by a striking sequence similarity of residues lining the
intrasubunit binding site (see alignment in SI Appendix, Fig. S1).
Mutagenesis studies in eukaryote GABAA receptors dem-
onstrated a large change in the ﬂurazepam EC50 for γ2-I76C
(17), which is a residue equivalent to G37 in the intrasubunit
benzodiazepine site in ELIC. However, further studies are war-
ranted to investigate a possible functional role of the intrasubunit
site in eukaryote receptors.
Intersubunit Benzodiazepine Site in ELIC. We obtained two addi-
tional crystal structures at 3.6-Å and 3.3-Å resolution from
crystals grown in the presence of equal amounts of Br-ﬂur-
azepam and GABA or zopiclone and GABA, respectively (Fig. 3
C–E). No crystals could be obtained in the absence of GABA or
at less than 1 mM Br-ﬂurazepam. The anomalous signal for the
bromine atom in Br-ﬂurazepam and the higher-resolution data
for zopiclone allowed us to assign ligand-binding poses with
certainty. Stereo ﬁgures of electron densities are shown in SI
Appendix, Figs. S8 and S9. For Br-ﬂurazepam (Fig. 3D) and
zopiclone (Fig. 3E), we observe clear Fourier Fo-Fc density (3σ)
and anomalous density (4σ) for the bromine atom in Br-ﬂur-
Fig. 3. Two different benzodiazepine-binding sites in ELIC. (A) Cross-section through a surface representation of the ELIC structure obtained from crystals
grown in the presence of excess GABA (10 mM) and 50 μM ﬂurazepam (FZM). One GABA molecule is shown as green spheres at the intersubunit binding site
composed of the principal (+) face (yellow) and the complementary (−) face (blue). Flurazepam is shown as red spheres and is localized at an intrasubunit
benzodiazepine site that faces the channel vestibule in ELIC. The view, perpendicular to the membrane, is a cartoon representation and shows only two
subunits of the pentamer. (B) (Left) A detailed view of GABA and ﬂurazepam, shown in sticks, and Fourier Fo-Fc density (shown as green mesh, contoured at
3σ). (Right) A detailed view of the opposing locations of the GABA- (green spheres) and ﬂurazepam- (red spheres) binding sites. GABA and ﬂurazepam are
localized at the same height but on opposing binding sites. (C–E) Same views as in A and B but for the ELIC structure obtained from crystals grown in the
presence of equal amounts (10 mM each) of GABA and Br-ﬂurazepam (Br-FZM) or of GABA and zopiclone (ZPC). At these concentrations, Br-ﬂurazepam and
zopiclone displace GABA and occupy the intersubunit benzodiazepine site. The green mesh is Fourier Fo-Fc density, contoured at 3σ, and the magenta mesh in
D is anomalous density for the bromine atom, contoured at 4.5 σ.
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azepam (magenta mesh in Fig. 3D) at ﬁve binding sites, which we
termed the “intersubunit benzodiazepine site” and which par-
tially overlaps the recognition site for GABA in crystal structure
for the low-ﬂurazepam concentration (Fig. 3A). No GABA could
be identiﬁed in the Br-ﬂurazepam and zopiclone density maps,
likely because benzodiazepines and zopiclone compete with higher
afﬁnity (micromolars) than GABA (millimolars) for a partially
overlapping binding site. Considerable overlap exists between the
GABA and the intersubunit benzodiazepine site, but the struc-
tural data allowed us to pinpoint a residue, F19, which is involved
in an interaction with benzodiazepines, but not GABA, because
it lies at the periphery of the intersubunit site. To investigate
whether the intersubunit benzodiazepine site mediates inhibitory
effects of ﬂurazepam on ELIC, we characterized the functional
effects of 50 μM and 500 μM ﬂurazepam on F19A mutants of
ELIC (SI Appendix, Fig. S7 A and C). In agreement with the
structural data, we ﬁnd that the F19A mutant still is activated by
GABA but no longer is inhibited by 500 μM ﬂurazepam. In
contrast, lower concentrations of ﬂurazepam (50 μM), still po-
tentiate the GABA response. Together, these data provide
clear evidence that the inhibitory effects on ELIC of ﬂurazepam
at >100 μM arise from an interaction at the intersubunit benzo-
diazepine site.
Detailed analysis of molecular interactions for Br-ﬂurazepam
(Fig. 4A) shows contributions of conserved aromatic residues
previously shown to be important for benzodiazepine actions on
GABAA receptors. These residues include F133 (loop B, ho-
mologous to Y159 in α1), F188 (loop C, homologous to Y209 in
α1), and Y38 (loop D, homologous to F77 in γ2). A notable
π-stacking of the bromophenyl moiety between Y175 (loop C)
and F19 can be observed, as can a π–π interaction between the
ﬂuorophenyl moiety and Y38 (loop D, F77 in the γ2-subunit). In
GABAA receptors, F19 corresponds to Y58 in the γ2-subunit,
which is located at the periphery of the intersubunit benzodiaz-
epine site and was identiﬁed previously as an important de-
terminant of benzodiazepine action termed “loop G” (2, 18).
Hydrogen bonds are formed with R91 and N103 in loop E, which
correspond to M130 and T142 in the γ2-subunit. Although Br-
ﬂurazepam occupies a pocket that resembles the location of the
α/γ interface in GABAA receptors, the bromine substituent on
position 7 of the phenyl moiety in ﬂurazepam points out of the
benzodiazepine pocket in ELIC. In contrast, previous photo-
labeling studies with ﬂunitrazepam (44) or experiments with
isothiocyanate substitutions at position 7 of diazepam (45, 46)
position this moiety near α1H101 of loop A in GABAA recep-
tors, a location deep inside the pocket (I79 in ELIC). Pre-
sumably, the divergent amino acid composition between ELIC
and the high-afﬁnity α/γ benzodiazepine site in GABAA recep-
tors causes differences in the pocket architecture and results in
different benzodiazepine-binding poses in ELIC. Nevertheless,
the observed binding interactions of Br-ﬂurazepam in ELIC may
assist in clarifying previously described inhibitory effects at >100
μM concentration of benzodiazepines, which could displace
GABA from the β/α interface in GABAA receptors (47).
Interestingly, we observed a preferential ﬁt in electron density
of the S-enantiomer of zopiclone even though the racemic mix-
ture was used for cocrystallization with ELIC (Fig. 3E and SI
Appendix, Fig. S9). This enantioselectivity corresponds to what is
known from S-zopiclone binding to the high-afﬁnity benzodiaz-
epine-binding site in GABAA receptors (48). Zopiclone features
extensive interactions (Fig. 4 B and C) with binding-site residues
deep inside the principal (+) face, including cation-π inter-
actions with F133 and F188 and hydrogen bonds with the car-
bonyl oxygen molecules of P132 and F133, which are interactions
not observed in the Br-ﬂurazepam structure (Fig. 4A). The hy-
drogen bond between the piperazine nitrogen of zopiclone and
the carbonyl oxygen of the conserved aromatic residue of loop
B (F133, which corresponds to Y159 in the α1-subunit) is strik-
ingly similar to the interaction between tertiary and quaternary
amines and the loop B aromat W145 in AChBP cocrystal struc-
tures (49). On the complementary (−) face, zopiclone is involved
in aromatic stacking with F19, which is homologous to Y58 in the
γ2-subunit. Similarly, V40 in ELIC corresponds to A79 in the
γ2-subunit, which is a crucial residue in zopiclone afﬁnity (48).
Taken together, zopiclone is involved in key interactions with
conserved aromatic residues, namely F19 (Y58 in γ2-subunit, loop
G), Y38 (F77 in the γ2-subunit, loop D), F133 (Y159 in α1-sub-
unit, loop B), and F188 (Y209 in α1-subunit, loop C), suggesting
that zopiclone adopts a binding pose that possibly mimics the
ligand orientation in the α/γ interface of the GABAA receptors.
Fig. 4. Molecular determinants of Br-ﬂurazepam and zopiclone recognition in ELIC and GABAA receptors. (A and B) Detailed view of ligand interactions of
Br-ﬂurazepam (Br-FZM) and zopiclone (ZPC) at the intersubunit benzodiazepine site in ELIC. Ligands are shown in yellow ball-and-stick representation.
Residues involved in ligand interactions are shown as white sticks on the principal (+) face and light-blue sticks on the complementary (−) face. Dashed lines
represent hydrogen bonds. (C) Chemical structure of zopiclone, with the surrounding ligand contacts in ELIC. Black dashed lines represent hydrophobic
interactions; red dashed lines represent hydrogen bonds. Superscript letters indicate the binding-site loop (A–G) at which each residue is located. Important
residues previously identiﬁed by mutagenesis at the high afﬁnity α/γ benzodiazepine site in GABAA receptors are indicated in gray next to homologous
residues in ELIC. Superscript letters indicate whether the residue was identiﬁed on the principal (+) face of the α1-subunit or the complementary (−) face of
the γ2-subunit.
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Benzodiazepines Induce Conformational Changes in the Binding
Pocket of ELIC. Upon binding of Br-ﬂurazepam, loop C under-
goes a signiﬁcant conformational movement (SI Appendix, Figs.
S10 and S11), similar to the outward extension of loop C ob-
served upon binding of certain partial agonists and antagonists in
AChBP (49). We quantiﬁed the outward movement of loop C by
measuring the distance between the F133 carbonyl oxygen and
Cα atom of L178, which is 17.1 ± 0.1 Å in the Br-ﬂurazepam
structure, 13.9 ± 0.1 Å in the zopiclone structure, 11.4 ± 0.1 Å in
GABA-bound ELIC, and 9.8 ± 0.3 Å in a closed-channel state of
ELIC (here termed “apo-ELIC”). Except for the conformational
change of loop C and local side-chain reorientations in the
binding pocket, ELIC in complex with GABA and modulators
shows an overall conformation that strongly resembles the pub-
lished ELIC structure (19), which is thought to represent apo-
ELIC. The GABA-bound ELIC structure can be superposed
onto apo-ELIC with a rmsd value of 0.59 Å (1,514 residues
aligned for pentamer 1) and 0.61 Å (1,512 residues aligned for
pentamer 2). No conformational changes can be observed that
resemble those in the GLIC (20, 21) and GluCl structures (22),
which are thought to resemble open-channel states. There are
two possible explanations for the lack of conformational changes
in the GABA-bound structure of ELIC. First, crystal lattice
contacts may stabilize ELIC in a closed, unactivated conformational
state. Alternatively, because our electrophysiological recordings
show that ELIC desensitizes over a time course of several
minutes during exposure to GABA, the GABA-bound structure
may represent a desensitized state, that resembles the published
apo-ELIC structure.
Concluding Remarks
GABAA receptors are critical for fast synaptic inhibition in the
mammalian brain and are the target of many therapeutic agents;
understanding their mechanism of action therefore has long
been an important goal. Our study, which reveals the critical
elements of both GABA and benzodiazepine recognition in
ELIC, brings this goal a step closer. We ﬁnd that GABA binds
at an intersubunit binding site using a range of interactions,
including a cation-π interaction as observed in GABAA and
GABAC receptors. Benzodiazepines can occupy two different
sites in ELIC: an intrasubunit site responsible for potentiating
effects, and an intersubunit site responsible for inhibitory effects,
which partially overlaps with the GABA-recognition site. In
eukaryote GABAA receptors there are at least three, but possibly
more, different low-afﬁnity binding sites for benzodiazepine-site
ligands in addition to the high-afﬁnity benzodiazepine-binding
site at the α/γ interface. One of these sites is the low-afﬁnity
diazepam-binding site described by Walters et al. (29). A second
site is a low-afﬁnity ﬂurazepam-binding site that likely localizes
to the α/β interface (28). A third site is a low-afﬁnity binding site
that accounts for the low-potency inhibition of the GABA cur-
rent in α/β receptors (47). This latter site corresponds to the
intersubunit benzodiazepine site in ELIC, which mediates in-
hibitory effects of ﬂurazepam. The location of the intrasubunit
benzodiazepines site in ELIC was unexpected, but if a similar site
exists in GABAA receptors, it could provide a framework for
understanding previously unexplained actions of benzodiaze-
pines on GABAA receptors.
Our study offers a structural view how GABA and allosteric
ligands are recognized, which is a key question in understanding
modulation of ligand-gated ion channels. Overall, this work
paves the way for structural elucidation of eukaryote GABA
receptors in the presence of different allosteric modulators.
Methods
Protein Production and Crystallization. ELIC was expressed and puriﬁed as
previously described with minor modiﬁcations. The ELIC sequence (GenBank
accession number ADN00343.1) was purchased from GenScript as a synthetic
gene with optimized codon use for expression in Escherichia coli. In the
published sequence of ELIC [Protein Data Bank (PDB) ID code 2VL0] a Gly
residue is missing after R163. Consequently, all residues after G164 are
renumbered +1 in our ELIC sequence. The synthetic gene corresponding to
mature ELIC with an N-terminal truncation (residue numbers 8–322) was
subcloned in pET-11a (Novagen) and N-terminally fused to maltose-binding
protein (MBP) with a 3CV protease cleavage site for removal of MBP. The
MBP-ELIC fusion protein was expressed in the C43 E. coli strain, which was
grown in LB medium supplemented with carbenicilline to an absorbance
A600 = 1.8. Upon addition of 0.2 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG), the temperature was lowered to 20 °C for overnight incubation. E. coli
membranes were isolated by ultracentrifugation at 125,000 × g at 4 °C for 1 h
after cell lysis with an Emulsiﬂex C-5 (Avestin) in 50 mM Na-phosphate (pH
8.0), 150 mM NaCl (buffer A), 1 mg/mL lysozyme, 20 μg/mL DNase, 5 mM
MgCl2, and the addition of protease inhibitors [either complete tablets
(Roche) with the addition of 1 mM PMSF or 1 μg/mL leupeptin, μg/mL pep-
statin, and 1 mM PMSF]. Membrane proteins were solubilized with 2%
(wt/vol) anagrade n-undecyl-β-D-maltoside (Anatrace) at 4 °C overnight, and
the solubilized fraction was cleared by ultracentrifugation at 30,000 × g at 4
°C for 1 h. Solubilized proteins were batch puriﬁed by afﬁnity chromatog-
raphy on amylose resin (New England Biolabs). After incubation with beads
for 1–2 h at 4 °C, the column was washed with three column volumes buffer
A + 0.15% n-undecyl-β-D-maltoside. The MBP-ELIC fusion protein was cleaved
overnight at 4 °C by incubation of the beads with 3CV protease in the presence
of 1 mM EDTA and 1 mM DTT. Cleaved ELIC and 3CV protease were passed
through the column and concentrated to less than 1 mL on a Vivaspin con-
centrating column with a cutoff of 100 kDa (Sartorius). ELIC was puriﬁed
further on a Superdex 200 10/300 GL (GE Healthcare) column equilibrated
with buffer containing 10 mM Na-phosphate (pH 8.0), 150 mM NaCl, and
0.15% n-undecyl-β-D-maltoside. Peak fractions corresponding to cleaved
pentameric ELIC were pooled, concentrated to 10 mg/mL, and supple-
mented with 0.5 mg/mL E. coli lipids (Avanti Polar Lipids).
Crystallization of ELIC was carried out at 4 °C by vapor diffusion of sitting
drops that were set up with a Mosquito crystallization robot in MRC plates
(Molecular Dimensions). The crystallization buffer was composed of 200 mM
ammonium sulfate, 50 mM ADA (N-(2-acetamido)iminodiacetic acid) (pH
6.5), and 9–12% (vol/vol) PEG4000. During the course of this study more than
1,000 crystals for different ELIC complexes were screened, and datasets were
collected when diffraction was better than 4.0 Å. Crystals for ELIC in complex
with GABA and allosteric modulators were obtained by screening in two
dimensions with a range of GABA concentrations from 100 μM to 100 mM
and a range of benzodiazepine (ﬂurazepam, ﬂunitrazepam, or bromaze-
pam) concentrations from 10 μM to 15 mM. The crystal structure of ELIC in
complex with GABA and ﬂurazepam was obtained from crystals grown in
the presence of 10 mM GABA and 50 μM ﬂurazepam. The crystal structures
for ELIC in complex with Br-ﬂurazepam and zopiclone were obtained by
screening with 10 mM GABA and a range of Br-ﬂurazepam or zopiclone
concentrations from 1–15 mM Br-ﬂurazepam or 0.05–10 mM zopiclone.
Anomalous diffraction data were collected from crystals grown in the
presence of 10 mM GABA and 10 mM Br-ﬂurazepam. No crystals were
obtained at Br-ﬂurazepam concentrations lower than 1 mM. No crystals
were obtained for Br-ﬂunitrazepam. Stock solutions for GABA and ﬂur-
azepam were made in milliQ water. The stock solutions for Br-ﬂurazepam,
Br-ﬂunitrazepam, ﬂunitrazepam, bromazepam, and zopiclone were made in
DMSO. Crystals were harvested after 1 wk by adding 30% (vol/vol) glycerol
as a cryoprotectant to the mother liquor. Crystals were cryo-cooled by im-
mersion in liquid nitrogen. The synthesis of Br-ﬂurazepam and Br-ﬂunitrazepam
is described in SI Appendix, Fig. S12.
Structure Determination and Reﬁnement. All crystals obtained in this study
belonged to the same spacegroup as the ELIC structure published by Hilf
and Dutzler (PDB ID code 2VL0). The dataset for GABA+ﬂurazepam was
obtained by merging partial datasets obtained by exposing a single crystal
at three different positions. For GABA+Br-ﬂurazepam the best quality in
electron density maps was obtained after merging ﬁve partial datasets
obtained by exposure on different positions of two isomorphous crystals.
Data integration was done in XDS and scaling either in XSCALE (GABA+Br-
ﬂurazepam, GABA+zopiclone) or SCALA (GABA+ﬂurazepam). Structure sol-
utions were obtained after molecular replacement with PHASER and re-
ﬁnement with REFMAC. Final model building and reﬁnement for the GABA
+ﬂurazepam structure was carried out by iterative cycles of manual re-
building in COOT and reﬁnement in PHENIX. The loops preceding and fol-
lowing the β8-strand in the extracellular domain were built incorrectly in
previously published ELIC structures (PDB ID codes 2VL0, 2YKS, 3RQU, 3RQW,
3UQ4, 3UQ5, and 3UQ7). In our structures, we have built residues 137–139 of
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the loop preceding β8 in a different conformation, resulting in a shift of the
β8-strand register by +2 residues. After residue 153 in the loop following the
β8-strand, our structures follow the same register as the previously published
structures. Ligand restraints for GABA, ﬂurazepam, Br-ﬂurazepam, and zopi-
clone were generated using ELBOW in the PHENIX suite or with PRODRG. In
PHENIX we used autoNCS to detect automatically noncrystallographic sym-
metry (NCS) restraints, which were maintained during reﬁnement for an en-
tire subunit per NCS group. One TLS (Translation/Libration/Screw) body was
assigned per subunit. Model validation was done using MOLPROBITY and all
ﬁgures were prepared using PYMOL (19).
Two-Electrode Voltage-Clamp Recordings. For electrophysiological recordings
from Xenopus oocytes, the mature sequence of ELIC (residue numbers
8–322) was cloned into pGEMHE with the signal sequence of the human α7
nAChR (MRCSPGGVWLALAASLLHVSLQ). mRNA was transcribed in vitro
using the mMESSAGE mMACHINE T7 transcription kit (Ambion). Mutants
were engineered using a QuikChange strategy (Stratagene) and veriﬁed
by sequencing.
For oocyte recordings stage V–VI Xenopus laevis oocytes were stored
and incubated at 18 °C in modiﬁed Barth’s medium [88 mM NaCl, 10 mM
Hepes-NaOH (pH 7.4), 2.4 mM NaHCO3, 1 mM KCl, 0.82 mM MgSO4, 0.41
mM CaCl2, 0.34 mM Ca(NO3)2] supplemented with 100 U/mL penicillin and 100
µg/mL streptomycin. Collagenase treatment (type IA, Sigma) and mechanical
defolliculation of the oocytes were performed as described (47). Oocytes were
injected with 10 ng RNA, and recordings were made 18–36 h postinjection.
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